Fig. 2From: Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The NetherlandsCost effectiveness acceptability curves. At a willingness to pay threshold of €20.000/QALY, RG-NACT is expected to be the optimal strategy with 94 and 95 % certainty under the current and full implementation scenarios respectivelyBack to article page